Drugs / STAR-001
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07431216 | May 2026 → May 2027 expected | glioblastoma | Starlight Therapeutics Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STAR-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07431216 ↗ |
| Known as | LP-184 | “STAR-001 (LP-184) will be administered via IV infusion over 30 (± 5) minutes on Day 1 and Day 8 of each 21-day cycle.” NCT07431216 ↗ |
| Route | Intravenous | “via IV infusion” NCT07431216 ↗ |